Fig. 1: High PRMT1 expression was related to adverse outcomes in MM patients. | Cell Death & Disease

Fig. 1: High PRMT1 expression was related to adverse outcomes in MM patients.

From: PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6

Fig. 1

A-C. PRMT1 expression in normal donors and MM patients (A), MM patients with different R-ISS stages (B), or MM patients with different ISS stages (C) in GSE6477 and GSE136324, respectively. D Kaplan-Meier survival analysis of overall survival rate in GSE4581. E ROC curve for MM with different myeloma stages. PRMT1 mRNA expression (F) and protein expression (G) in primary bone marrow mononuclear cells from NDMM and normal donors. H Nomogram predicting 1-, 3-, and 5-year OS for MM patients based on PRMT1 and other prognostic parameters. I ROC curve for the nomogram prognosis system. J Calibration plot of the nomogram for 1-year, 2-year, and 3-year OS. (K) Kaplan-Meier survival analysis for total points of Nomogram. Data represent the mean ± SD.* p < 0.05, ** p < 0.01, *** p < 0.001.

Back to article page